# Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Source: https://onco.cc/trials/nct05549297/  
OnCo record `nct05549297` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tebentafusp, Pembrolizumab in melanoma, run by Immunocore Ltd, now recruiting.

## Summary

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) is a phase 3 interventional study registered as NCT05549297 by Immunocore Ltd, with 540 participants planned, started 2022-12-19 and due to reach its primary completion in 2028-03. Interventions recorded: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice. Conditions listed: Advanced Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05549297
- Phase: 3
- Setting: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
- Sponsor: Immunocore Ltd
- Enrolled: 540

## Sources

- ClinicalTrials.gov NCT05549297: https://clinicaltrials.gov/study/NCT05549297

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- companies: [Immunocore](https://onco.cc/companies/immunocore/)

---
JSON: https://onco.cc/api/v1/entities/nct05549297.json